[{"id":"b3fcd5d4-2376-4a44-a782-f5af77183569","acronym":"LEAHRN","url":"https://clinicaltrials.gov/study/NCT02724579","created_at":"2021-01-18T13:20:08.012Z","updated_at":"2025-02-25T15:10:23.410Z","phase":"Phase 2","brief_title":"Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma","source_id_and_acronym":"NCT02724579 - LEAHRN","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN • CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["MYCN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • vincristine • lomustine • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 11/17/2017","start_date":" 11/17/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-13"},{"id":"79a21cb0-b80b-4f09-9b9e-bdba02cd1248","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT01505400","created_at":"2021-01-18T06:19:22.670Z","updated_at":"2025-02-25T16:58:29.958Z","phase":"","brief_title":"Integrated Molecular Profiling in Advanced Cancers Trial","source_id_and_acronym":"NCT01505400 - IMPACT","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3026","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"1f0415b7-1012-4eac-85aa-31006ac84270","acronym":"","url":"https://clinicaltrials.gov/study/NCT06718153","created_at":"2025-02-26T10:22:38.573Z","updated_at":"2025-02-26T10:22:38.573Z","phase":"","brief_title":"Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation","source_id_and_acronym":"NCT06718153","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" TP53 • TERT • CTNNB1","pipe":"","alterations":" ","tags":["TP53 • TERT • CTNNB1"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/23/2024","start_date":" 10/23/2024","primary_txt":" Primary completion: 05/13/2025","primary_completion_date":" 05/13/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-12-05"},{"id":"0340b14e-a127-4e74-868c-fbd3285909ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05761951","created_at":"2023-03-09T15:01:38.080Z","updated_at":"2025-02-25T16:18:37.564Z","phase":"Phase 2","brief_title":"Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT05761951","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CTNNB1 • AXIN1 • RSPO2 • ZNRF3","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • AXIN1 • RSPO2 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sirexatamab (DKN-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/29/2023","start_date":" 08/29/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2029","study_completion_date":" 01/31/2029","last_update_posted":"2024-11-18"},{"id":"072b5222-7280-4f30-8150-3b6f5d947d3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02228681","created_at":"2024-01-03T20:17:23.392Z","updated_at":"2025-02-25T15:41:52.541Z","phase":"Phase 2","brief_title":"Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer","source_id_and_acronym":"NCT02228681","lead_sponsor":"GOG Foundation","biomarkers":" PIK3CA • PGR • PTEN • CTNNB1","pipe":" | ","alterations":" KRAS mutation • PIK3CA mutation","tags":["PIK3CA • PGR • PTEN • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • tamoxifen • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 05/21/2015","start_date":" 05/21/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 08/22/2024","study_completion_date":" 08/22/2024","last_update_posted":"2024-09-19"},{"id":"a47ddf13-3816-49fc-80b2-c615e6b61c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03264664","created_at":"2023-11-04T04:12:31.080Z","updated_at":"2024-07-02T16:34:27.421Z","phase":"Phase 1","brief_title":"Study of E7386 in Participants With Selected Advanced Neoplasms","source_id_and_acronym":"NCT03264664","lead_sponsor":"Eisai Inc.","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-11"},{"id":"6197c2dd-dcac-48ae-964b-1bb53f9a93dc","acronym":"FOG-001-101","url":"https://clinicaltrials.gov/study/NCT05919264","created_at":"2023-06-26T14:09:21.574Z","updated_at":"2024-07-02T16:34:36.852Z","phase":"Phase 1/2","brief_title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05919264 - FOG-001-101","lead_sponsor":"Fog Pharmaceuticals, Inc.","biomarkers":" MSI • CTNNB1","pipe":" | ","alterations":" MYC expression","tags":["MSI • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zolucatetide (FOG-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2024-06-10"},{"id":"8326d952-c482-49fa-825b-eb6a21c8a525","acronym":"ALTITUDES","url":"https://clinicaltrials.gov/study/NCT02867033","created_at":"2021-01-18T14:04:27.919Z","updated_at":"2024-07-02T16:35:00.172Z","phase":"","brief_title":"National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)","source_id_and_acronym":"NCT02867033 - ALTITUDES","lead_sponsor":"Centre Oscar Lambret","biomarkers":" CTNNB1 • APC","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 628","initiation":"Initiation: 03/22/2016","start_date":" 03/22/2016","primary_txt":" Primary completion: 11/01/2030","primary_completion_date":" 11/01/2030","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-05-30"},{"id":"00386017-fdba-4646-91db-e52d18a56ce7","acronym":"PEPN2011","url":"https://clinicaltrials.gov/study/NCT04851119","created_at":"2021-04-20T14:55:40.726Z","updated_at":"2024-07-02T16:35:08.278Z","phase":"Phase 1/2","brief_title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","source_id_and_acronym":"NCT04851119 - PEPN2011","lead_sponsor":"Children's Oncology Group","biomarkers":" RNF43 • CTNNB1 • TCF7L2","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P","tags":["RNF43 • CTNNB1 • TCF7L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation • CTNNB1 S45P"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tegavivint (BC2059)"],"overall_status":"Recruiting","enrollment":" Enrollment 147","initiation":"Initiation: 11/08/2021","start_date":" 11/08/2021","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-04-22"},{"id":"ca6866f9-37af-4ed6-b384-0ce5df98af8a","acronym":"NCI-2018-01284","url":"https://clinicaltrials.gov/study/NCT03008408","created_at":"2021-01-18T14:48:06.189Z","updated_at":"2024-07-02T16:35:11.704Z","phase":"Phase 2","brief_title":"A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT03008408 - NCI-2018-01284","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 08/31/2028","primary_completion_date":" 08/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-04-03"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"4d7f225a-7afa-4e5a-a31b-96fb1c3ee410","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195399","created_at":"2021-01-18T20:26:44.866Z","updated_at":"2024-07-02T16:35:16.137Z","phase":"Phase 2","brief_title":"A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery","source_id_and_acronym":"NCT04195399","lead_sponsor":"Children's Oncology Group","biomarkers":" CD8 • CTNNB1 • APC • CD4","pipe":" | ","alterations":" APC mutation","tags":["CD8 • CTNNB1 • APC • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ogsiveo (nirogacestat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-06"},{"id":"d12ed1b0-b992-49c6-901f-82ccd2d8297b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03610906","created_at":"2021-01-18T17:44:58.482Z","updated_at":"2024-07-02T16:35:17.170Z","phase":"","brief_title":"Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy","source_id_and_acronym":"NCT03610906","lead_sponsor":"University of Colorado, Denver","biomarkers":" CTNNB1","pipe":"","alterations":" ","tags":["CTNNB1"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 250","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 02/02/2030","primary_completion_date":" 02/02/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-02-28"},{"id":"98f9903f-5399-470c-a4e4-810aaee0f5a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681248","created_at":"2022-08-29T14:58:12.640Z","updated_at":"2024-07-02T16:35:35.195Z","phase":"","brief_title":"Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT04681248","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":"","alterations":" ","tags":["RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirexatamab (DKN-01)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-09-29"},{"id":"6a7cc96b-1a8d-4c60-a5b9-6a9e7c5f86aa","acronym":"NBIBLI","url":"https://clinicaltrials.gov/study/NCT03748667","created_at":"2021-08-02T20:53:11.763Z","updated_at":"2024-07-02T16:35:36.493Z","phase":"","brief_title":"Accuracy for Predicting Deep Submucosal Invasion","source_id_and_acronym":"NCT03748667 - NBIBLI","lead_sponsor":"Althaia Xarxa Assistencial Universitària de Manresa","biomarkers":" EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • TP53 • PIK3CA • PTEN • HRAS • CDKN2A • ARID1A • CTNNB1 • FBXW7 • KMT2C • MUC16 • POLD1 • SETD2 • ARID2 • FAT4 • CSMD1 • DAPK1 • SYNE1 • PCLO • RYR3 • ZFHX4"],"overall_status":"Completed","enrollment":" Enrollment 426","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 09/28/2022","primary_completion_date":" 09/28/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-09-21"},{"id":"fb8dc3ab-b4a9-4b4d-aae6-7233509f61b6","acronym":"Neo Combi","url":"https://clinicaltrials.gov/study/NCT01972347","created_at":"2021-03-01T20:52:35.949Z","updated_at":"2024-07-02T16:35:38.660Z","phase":"Phase 2","brief_title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","source_id_and_acronym":"NCT01972347 - Neo Combi","lead_sponsor":"Melanoma Institute Australia","biomarkers":" EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["EGFR • CD20 • CD8 • PD-1 • CCND1 • MCL1 • IL6 • CTNNB1 • TNFA • CD163 • CD4 • IL10 • CD68 • IL18 • FOXP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 05/04/2017","primary_completion_date":" 05/04/2017","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-30"},{"id":"2fd38c52-b64b-4e26-aac4-6e079d9c3e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991947","created_at":"2023-08-15T19:10:06.072Z","updated_at":"2024-07-02T16:35:39.996Z","phase":"","brief_title":"Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer","source_id_and_acronym":"NCT05991947","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-15"},{"id":"a20d813c-0be4-46f6-9eac-b9a7b8cfecb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187767","created_at":"2022-01-12T15:53:45.698Z","updated_at":"2024-07-02T16:36:00.723Z","phase":"","brief_title":"Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs","source_id_and_acronym":"NCT05187767","lead_sponsor":"University of Roma La Sapienza","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-11-08"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"c05e0fd8-f927-4e8c-a832-08281974edc0","acronym":"ABRADES","url":"https://clinicaltrials.gov/study/NCT03275818","created_at":"2021-01-18T16:10:41.239Z","updated_at":"2024-07-02T16:36:09.269Z","phase":"Phase 2","brief_title":"Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT03275818 - ABRADES","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" CTNNB1 • SPARC","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • SPARC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 05/09/2017","start_date":" 05/09/2017","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 09/30/2021","study_completion_date":" 09/30/2021","last_update_posted":"2022-06-07"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"8e871962-d882-425c-bf52-00aaa004787b","acronym":"Keynote 596","url":"https://clinicaltrials.gov/study/NCT02675946","created_at":"2022-01-26T19:54:54.091Z","updated_at":"2025-02-25T16:04:17.687Z","phase":"Phase 1b","brief_title":"CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)","source_id_and_acronym":"NCT02675946 - Keynote 596","lead_sponsor":"Curegenix Inc.","biomarkers":" BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF • RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • CGX1321"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2022-01-26"},{"id":"7f0b2055-2792-4c2b-a9ad-9dc67fd8b63b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02914977","created_at":"2021-01-18T14:18:37.925Z","updated_at":"2024-07-02T16:36:18.463Z","phase":"Phase 1","brief_title":"Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia","source_id_and_acronym":"NCT02914977","lead_sponsor":"Tara Lin","biomarkers":" CTNNB1","pipe":"","alterations":" ","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 04/03/2019","primary_completion_date":" 04/03/2019","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2022-01-14"},{"id":"95e30619-7cb6-49e5-a70d-9b038aaf7b08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02425800","created_at":"2021-01-18T11:36:14.829Z","updated_at":"2024-07-02T16:36:25.031Z","phase":"","brief_title":"Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells","source_id_and_acronym":"NCT02425800","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" CTNNB1 • CDH1","pipe":" | ","alterations":" TROP2 positive","tags":["CTNNB1 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2015","start_date":" 07/28/2015","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 08/03/2021","study_completion_date":" 08/03/2021","last_update_posted":"2021-09-01"}]